Abbott Laboratories (ABT)
$
131.37
-0.09 (-0.07%)
Key metrics
Financial statements
Free cash flow per share
3.8249
Market cap
228.6 Billion
Price to sales ratio
5.3039
Debt to equity
0.2713
Current ratio
1.7805
Income quality
0.6629
Average inventory
6.4 Billion
ROE
0.3184
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abbott Laboratories, along with its subsidiaries, is engaged in the discovery, development, manufacturing, and global sale of health care products, operating across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The EBITDA is $10,834,000,000.00 a key indicator of the company's operational profitability. Within the Established Pharmaceutical Products segment, the company markets generic pharmaceuticals to address conditions such as pancreatic exocrine insufficiency and dyslipidemia, as well as providing critical anti-infectives like clarithromycin and an influenza vaccine. The operating expenses amount to $14,474,000,000.00 encompassing various operational costs incurred, while the company reported selling, general, and administrative expenses of $11,651,000,000.00 indicating its operational overhead costs. Furthermore, the diluted EPS is $7.64 accounting for potential share dilution. The Diagnostic Products segment enhances health care with laboratory systems focused on immunoassay and clinical chemistry, alongside molecular diagnostics for infectious agents. The Nutritional Products segment delivers essential nutritional solutions for both pediatric and adult populations, while the Medical Devices segment offers innovative treatments for cardiovascular diseases and diabetes management. Abbott Laboratories, founded in 1888 and based in North Chicago, Illinois, has established itself as a leader in the health care sector. The stock is reasonably priced at $132.03 appealing to a broad range of investors. With a large market capitalization of $228,644,230,200.00 the company is a dominant player in the health care industry, contributing significantly to the overall market landscape. The stock has a high average trading volume of 6,472,595.00 indicating strong liquidity. It is a key player in the Medical - Devices industry, driving innovation and growth, and belongs to the Healthcare sector, further affirming its stature within the competitive health care market. Abbott Laboratories’ commitment to advancement and quality in health care solutions continues to position it for sustained success and relevance.
Is Abbott Laboratories (ABT) a good investment?
Investing in Abbott Laboratories (ABT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Abbott Laboratories (ABT)'s stock forecast?
Analysts predict Abbott Laboratories stock to fluctuate between $110.86 (low) and $141.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Abbott Laboratories's market capitalization?
As of 2025-08-29, Abbott Laboratories's market cap is $228,644,230,200, based on 1,740,460,000 outstanding shares.
How does Abbott Laboratories compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Abbott Laboratories has a Lower Market-Cap, indicating a difference in performance.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays dividends. The current dividend yield is 1.76%, with a payout of $0.59 per share.
How can I buy Abbott Laboratories (ABT) stock?
To buy Abbott Laboratories (ABT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABT. Place an order (Market, Limit, etc.).
What is the best time to invest in Abbott Laboratories?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Abbott Laboratories stock ever split?
Abbott Laboratories's last stock split was 5000:2399 on 2013-01-02.
How did Abbott Laboratories perform in the last earnings report?
Revenue: $41,950,000,000 | EPS: $7.74 | Growth: 134.55%.
Where can I find Abbott Laboratories's investor relations reports?
Visit https://www.abbott.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Abbott Laboratories?
You can explore historical data from here
What is the all-time high and low for Abbott Laboratories stock?
All-time high: $142.60 (2021-12-27) | All-time low: $89.67 (2023-10-12).
What are the key trends affecting Abbott Laboratories stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Investors are showing growing interest in the rapidly expanding structural heart device market, which is expected to witness a compound annual growth rate (CAGR) of 13.5% between 2025 and 2033, according to Grand View Research. Abbott Laboratories ABT and Edwards Lifesciences EW are two key players with significant presence in this sector.
prnewswire.com
Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical risk CE Mark is based on safety and effectiveness data from the VANTAGE trial presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in JACC: Cardiovascular Interventions Updated guidelines announced for the management of valvular heart disease provide further support for mitral and tricuspid therapies like MitraClip™ and TriClip™ for leaky heart valves ABBOTT PARK, Ill., Aug. 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for an expanded indication for the company's Navitor™ transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery.
youtube.com
An inside look into Abbott's momentum across diagnostics and devices, tariff impacts, and how AI will transform healthcare within five years. Transcript: CAROLINE WOODS: Joining me now, Robert Ford, CEO of Abbott.
zacks.com
ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.
zacks.com
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
zacks.com
ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.
zacks.com
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
reuters.com
Drugmaker Abbott India reported an 11.5% rise in first-quarter profit on Tuesday, driven by healthy sales in its mainstay pharmaceuticals segment.
seekingalpha.com
Abbott's Q2 performance reflects some evenness and the potential headwinds from macroeconomic uncertainties. However, short-term issues like tariffs and drug price control do not fundamentally alter Abbott's long-term moat. As a dividend aristocrat, its fundamental and valuation risks are better gauged by its dividend payouts than accounting EPS.
zacks.com
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
See all news
